Given that mutations in Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules play a key role in the pathogenesis and progression of DLBCL, various downstream targets are being developed to obtain clinical therapeutic benefits [4]. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.